

REPORT 3 OF THE COUNCIL ON SCIENCE AND PUBLIC HEALTH (I-09)  
Use of Cannabis for Medicinal Purposes  
(Resolutions 910, I-08; 921, I-08; and 229, A-09)  
(Reference Committee K)

EXECUTIVE SUMMARY

Objective. This report: (1) provides a brief historical perspective on the use of cannabis as medicine; (2) examines the current federal and state-based legal envelope relevant to the medical use of cannabis; (3) provides a brief overview of our current understanding of the pharmacology and physiology of the endocannabinoid system; (4) reviews clinical trials on the relative safety and efficacy of smoked cannabis and botanical-based products; and (5) places this information in perspective with respect to the current drug regulatory framework.

Data Sources. English-language reports on studies using human subjects were selected from a PubMed search of the literature from 2000 to August 2009 using the MeSH terms “marijuana” “cannabis,” and tetrahydrocannabinol,” or “cannabinoids,” in combination with “drug effects,” “therapeutic use,” “administration & dosage,” “smoking,” “metabolism,” “physiology,” “adverse effects,” and “pharmacology.” Additionally the terms “abuse/epidemiology,” and “receptors, cannabinoid” in combination with “agonists,” or “antagonists & inhibitors” as well as “endocannabinoids,” in combination with “pharmacology,” “physiology,” or “metabolism” were used. Additional articles were identified by manual review of the references cited in these publications. Web sites of the Food and Drug Administration, Drug Enforcement Administration, National Institute on Drug Abuse, Marijuana Policy Project, ProCon.org, and the International Association for Cannabis as Medicine also were searched for relevant resources.

Results. The cannabis sativa plant contains more than 60 unique structurally related chemicals (phytocannabinoids). Thirteen states have enacted laws to remove state-level criminal penalties for possessing marijuana for qualifying patients, however the federal government refuses to recognize that the cannabis plant has an accepted medical benefit. Despite the public controversy, less than 20 small randomized controlled trials of short duration involving ~300 patients have been conducted over the last 35 years on smoked cannabis. Many others have been conducted on FDA-approved oral preparations of THC and synthetic analogues, and more recently on botanical extracts of cannabis. Federal court cases have upheld the privileges of doctor-patient discussions on the use of cannabis for medicinal purposes but also preserved the right of the federal government to prosecute patients using cannabis for medicinal purposes. Efforts to reschedule marijuana from Schedule I of the Controlled Substances Act have been unsuccessful to date. Disagreements persist about the long term consequences of marijuana use for medicinal purposes.

Conclusions. Results of short term controlled trials indicate that smoked cannabis reduces neuropathic pain, improves appetite and caloric intake especially in patients with reduced muscle mass, and may relieve spasticity and pain in patients with multiple sclerosis. However, the patchwork of state-based systems that have been established for “medical marijuana” is woefully inadequate in establishing even rudimentary safeguards that normally would be applied to the appropriate clinical use of psychoactive substances. The future of cannabinoid-based medicine lies in the rapidly evolving field of botanical drug substance development, as well as the design of molecules that target various aspects of the endocannabinoid system. To the extent that rescheduling marijuana out of Schedule I will benefit this effort, such a move can be supported.

REPORT OF THE COUNCIL ON SCIENCE AND PUBLIC HEALTH

CSAPH Report 3-I-09

Subject: Use of Cannabis for Medicinal Purposes

Presented by: C. Alvin Head, MD, Chair

Referred to: Reference Committee K  
(Peter C. Amadio, MD, Chair)

---

1 This report responds to three resolutions related to the use of marijuana for medicinal purposes.

2  
3 Resolution 910 (I-08), submitted by the Medical Student Section and referred to the Board of  
4 Trustees (BOT), asked:

5  
6 That our American Medical Association (AMA) support reclassification of marijuana’s status  
7 as a Schedule I controlled substance into a more appropriate schedule.

8  
9 Resolution 921 (I-08), submitted by the Washington Delegation and referred to the BOT, asked:

10  
11 That our AMA support reclassification of marijuana’s status from a Schedule I controlled  
12 substance to a more appropriate schedule; and

13  
14 That our AMA support efforts to cease criminal prosecution and other enforcement actions  
15 against physicians and patients acting in accordance with states’ medical marijuana laws.

16  
17 Resolution 229 (A-09), submitted by the New York Delegation and referred to the BOT, asked:

18  
19 That our AMA offer assistance in seeking clear, indisputable confirmation from the federal  
20 government that physicians who follow the proposed New York State legislation if passed and  
21 regulation when subsequently developed will not be prosecuted for allegedly failing to follow  
22 the Presidential order still in place making it illegal for a physician to prescribe or even advise  
23 a patient to use marijuana for medical purposes; and

24  
25 That our AMA seek a reversal of the Executive Order itself that makes it illegal for a physician  
26 to prescribe or advise medical marijuana.

27  
28 The Council has issued two previous reports on “Medical Marijuana” in 1997 and 2001.<sup>1,2</sup> The first  
29 report is the basis for the current AMA policy on medical marijuana (Policy H-95.992, AMA  
30 Policy Database (Appendix A)) and was developed largely in response to emerging state initiatives  
31 designed to facilitate the medical use of marijuana. The second report in 2001 reviewed legal,  
32 regulatory, and scientific developments on this topic that had transpired since the first report. As of  
33 2001, the Council had concluded that sufficient evidence existed to support further research on the  
34 potential use of marijuana:

- 35  
36 • In HIV-infected patients with cachexia, neuropathy, or chronic pain, or who are suffering  
37 adverse effects from medication, such as nausea, vomiting, and peripheral neuropathy, that  
38 impede compliance with antiretroviral therapy;

- 1 • In patients undergoing chemotherapy, especially those being treated for mucositis, nausea, and  
2 anorexia, and those patients who do not obtain adequate relief from either acute or delayed  
3 emetic episodes from standard therapy;
- 4 • To potentiate the analgesic effects of opioids and to reduce their emetic effects in the treatment  
5 of postoperative, traumatic, or cancer pain;
- 6 • In patients suffering from spasticity or pain due to spinal cord injury, or neuropathic or central  
7 pain syndromes; and
- 8 • In patients with chronic pain and insomnia.

9  
10 In 2001, the AMA House of Delegates reaffirmed that marijuana should be retained in Schedule I  
11 of the Controlled Substances Act pending the outcome of further controlled studies.

12  
13 The Institute of Medicine (IOM) published a comprehensive report in 1999 commissioned by the  
14 Office of National Drug Control Policy, entitled “Marijuana and Medicine: Assessing the Science  
15 Base.”<sup>3</sup> The findings in this report (see Appendix B) generally agreed with the Council’s  
16 assessment of the evidence on the potential medical utility of synthetic and plant-derived  
17 cannabinoids. The IOM report also concurred with the Council that further research on the medical  
18 utility of marijuana and individual cannabinoids was warranted and that resources should be  
19 devoted to developing alternative, smoke-free delivery systems. The IOM further noted:

20  
21 “because marijuana is a crude THC delivery system that also delivers harmful substances,  
22 smoked marijuana should generally not be recommended for medical use. Nonetheless,  
23 marijuana is widely used by certain patient groups, which raises both safety and efficacy  
24 issues. If there is any future for marijuana as a medicine, it lies in its isolated components, the  
25 cannabinoids and their synthetic derivatives. Isolated cannabinoids will provide more reliable  
26 effects than crude plant mixtures. Therefore, the purpose of clinical trials of smoked marijuana  
27 would not be to develop marijuana as a licensed drug but rather to serve as a first step toward  
28 the development of nonsmoked rapid-onset cannabinoid delivery systems.”

29  
30 Accordingly, the IOM report supported the availability of a compassionate-use protocol as an  
31 interim measure whereby the clinical use of medical cannabis would be allowed for symptom relief  
32 in seriously ill patients in limited and locally implemented peer-reviewed treatment trials. Recently  
33 the American College of Physicians (ACP) issued a policy statement on medical marijuana  
34 (Appendix C).<sup>4</sup> Like the AMA, the ACP supports approaches to conduct rigorous scientific  
35 evaluation of the potential therapeutic benefits of marijuana, and development of non-smoked  
36 forms. Additionally, ACP urged federal review of marijuana’s status as a Schedule I substance to  
37 determine if it should be reclassified, and strongly supported exemption from federal criminal  
38 prosecutions, civil liability, or professional sanctions for physicians who issue recommendations  
39 for medical marijuana in accordance with state law, as well as protection from criminal or civil  
40 penalties for patients under such circumstances.

41  
42 In light of the foregoing discussion, this report evaluates the merits of Resolutions 910 (I-08), 921  
43 (I-08) and 229 (A-09). In so doing, the Council: (1) provides a brief historical perspective on the  
44 use of cannabis as medicine; (2) examines the current federal and state-based legal envelope  
45 relevant to the medical use of cannabis; (3) provides a brief overview of our current understanding  
46 of the pharmacology and physiology of endogenous cannabinoid receptors and substances  
47 (endocannabinoids); (4) reviews the more recent clinical trial evidence on the relative safety and  
48 efficacy of smoked cannabis and other cannabis-based products; and (5) places this information in  
49 perspective with respect to the current drug regulatory framework, and the rights and  
50 responsibilities of physicians to provide optimal care for their patients. In many places the term

1 “cannabis” is used. Marijuana is a slang term for the dried flowers and bracts of the cannabis plant.  
2 In cases where the term “marihuana” or “marijuana” is used in the statute, policy statement or other  
3 legal way, such terms are retained.

#### 4 5 METHODS

6  
7 English-language reports on studies using human subjects were selected from a PubMed search of  
8 the literature from 2000 to August 2009 using the MeSH terms “marijuana” “cannabis,” and  
9 tetrahydrocannabinol,” or “cannabinoids,” in combination with “drug effects,” “therapeutic use,”  
10 “administration & dosage,” “smoking,” “metabolism,” “physiology,” “adverse effects,” and  
11 “pharmacology.” Additionally the terms “abuse/epidemiology,” and “receptors, cannabinoid” in  
12 combination with “agonists,” or “antagonists & inhibitors” as well as “endocannabinoids,” in  
13 combination with “pharmacology,” “physiology,” or “metabolism” were used. Additional articles  
14 were identified by manual review of the references cited in these publications. Web sites of the  
15 Food and Drug Administration, Drug Enforcement Administration, National Institute on Drug  
16 Abuse, Marijuana Policy Project, ProCon.org, and the International Association for Cannabis as  
17 Medicine also were searched for relevant resources.

#### 18 19 BACKGROUND

20  
21 Cannabis is one of the oldest psychotropic drugs in human history. Originating from central Asia,  
22 and then spreading to China and India, the first modern description of its pharmacological  
23 properties was provided by an Irish physician (William O’Shaughnessy) in 1839.<sup>5</sup> First listed in  
24 the United States Dispensary in 1854, cannabis was promoted for a variety of conditions based on  
25 its putative analgesic, sedative, anti-inflammatory, antispasmodic, anti-asthmatic, and  
26 anticonvulsant properties.<sup>1,6,7</sup> Many cannabis-containing oral extracts and tinctures were  
27 subsequently manufactured. Interest in the medical use of cannabis waned somewhat in the late  
28 nineteenth and early twentieth centuries with the advent of opiates, barbiturates, chloral hydrate,  
29 and aspirin and the widespread availability of hypodermic syringes for injection of water-soluble  
30 compounds. Nevertheless, cannabis remained available in the British Pharmacopoeia in extract  
31 and tincture form until 1971.

32  
33 The U.S. government and popular media began condemning the use of smoked cannabis in the  
34 1930s, linking its use to homicidal mania. The Marihuana Tax Act of 1937 introduced the first  
35 federal restrictions on marijuana. This federal law required industrial or medical users to register  
36 and pay a tax on marijuana of \$1/ounce. Individuals using marijuana for recreational or other  
37 purposes were required to pay a tax of \$100/ounce. A combination of the paperwork required of  
38 physicians who wished to use the drug in their practice, and regulations later imposed by the  
39 Federal Bureau of Narcotics designed to prevent diversion, quickly dampened enthusiasm for  
40 pursuing medical applications of cannabis.

41  
42 At the time, the AMA was virtually alone in opposing passage of the Marihuana Tax Act. The  
43 AMA believed that objective data were lacking on the harmful effects of marijuana, and that  
44 passage of the Act would impede future investigations into its potential medical uses.<sup>8</sup> The AMA’s  
45 Committee on Legislative Activities recommended that marijuana’s status as a medicinal agent be  
46 maintained.<sup>9</sup> Nevertheless, secondary to governmental pressures, marijuana was removed from the  
47 U.S. Pharmacopoeia in 1942, thus losing its remaining mantle of therapeutic legitimacy.

48  
49 In 1964, delta-9-tetrahydrocannabinol (hereafter referred to as THC) was identified as the primary  
50 psychoactive cannabinoid in *Cannabis sativa* (see below) and successfully synthesized.<sup>10</sup> The  
51 1960s witnessed a resurgence in the recreational use of smoked cannabis, and the ability of

1 cannabis to relieve certain disease symptoms was “rediscovered.” Thereafter the recreational and  
 2 “medical” forms of smoked cannabis became merged. This contrasts with the path of medicinal  
 3 opioid development and the recreational use of smoked botanical opium, which became clearly  
 4 distinct.

5  
 6 Receptors in the brain and periphery that bind THC (cannabinoid receptors) were discovered in the  
 7 early 1990s, and the identification of endogenous compounds that act at cannabinoid receptors  
 8 (endocannabinoids) soon followed. The last decade has seen an explosion in research about the  
 9 “endocannabinoid system” (see below). Information gleaned from these investigations has shed  
 10 light on the pharmacologic activity of phytocannabinoids, and created opportunities for the  
 11 development of pharmaceuticals interacting with this system.

## 12 13 CANNABINOIDS AND THE ENDOCANNABINOID SYSTEM

14  
 15 *Cannabis Sativa*. The plant contains over 400 chemical compounds.<sup>11</sup> The main psychoactive  
 16 substance is generally believed to be THC, but more than 60 other cannabinoids (C<sub>21</sub>-containing  
 17 compounds) have been identified in the plant (phytocannabinoids) and pyrolysis products.<sup>10-12</sup>  
 18 Cannabinoids are chemical compounds that are unique to the cannabis plant. Delta-8-THC is  
 19 similar in potency to THC, but is present in only small concentrations.<sup>13</sup> Cannabinol and  
 20 cannabidiol are the other major cannabinoids present. The former is slightly psychoactive, but not  
 21 in the amounts delivered by smoking marijuana.<sup>13</sup> Cannabidiol is not psychoactive and has  
 22 distinctive properties (see below). The average content of THC in cannabis plants is highly  
 23 variable depending on the strain, climate, soil and growing conditions, and handling after harvest.<sup>14</sup>  
 24 THC is a resinous weak acid, pKa = 10.6, with a very high lipid solubility and very low aqueous  
 25 solubility.<sup>15</sup> It binds to glass, diffuses into plastic, and is photo labile and susceptible to heat, acid,  
 26 and oxidation; these characteristics have served as barriers to the development of traditional  
 27 pharmaceutical dosage forms. The (-) enantiomer is up to 100 times more potent than the (+)  
 28 enantiomer depending on the pharmacological test.<sup>16</sup>

## 29 30 ENDOCANNABINOIDS

### 31 32 *Cannabinoid Receptors*

33  
 34 Two types of cannabinoid receptors (CB1 and CB2) have been clearly identified and both are  
 35 members of the superfamily of G-protein-coupled receptors. The CB1 receptor, first cloned in  
 36 1990, is mainly expressed in the brain and spinal cord.<sup>17</sup> Distribution is heterogeneous with the  
 37 highest densities present in the basal ganglia, hippocampus, and cerebellum, with comparatively  
 38 fewer receptors in the brainstem.<sup>18,19</sup> CB1 receptors are among the most abundant G-protein  
 39 coupled receptors in the brain.<sup>20</sup> By coupling predominately to inhibitory G proteins, CB1 receptors  
 40 inhibit certain inwardly directed calcium channels, activate outwardly directed potassium channels,  
 41 and activate various mitogen-activated protein (MAP) kinases.<sup>21</sup> The latter may play a role in the  
 42 modulation of synaptic plasticity, cell migration, and neurite remodeling. CB1 receptors are  
 43 located on the terminals of central and peripheral neurons. Generally, their activation inhibits the  
 44 ongoing release of a number of different excitatory and inhibitory transmitters, or hyperpolarizes  
 45 neurons, which also inhibits activity.<sup>21</sup>

46  
 47 The CB2 receptor, first cloned in 1993 is predominantly expressed in cells of the immune and  
 48 hematopoietic systems but also is present in nonparenchymal cells of the liver, endocrine pancreas,  
 49 and bone.<sup>22</sup> Some CB2 receptors also are functionally expressed in the CNS, notably on microglial  
 50 cells.<sup>23,24</sup> CB2 receptor activation alters the release of cytokines from immune cells and participates

1 in the regulation immune function.<sup>20</sup> CB2 agonists generally suppress the functions of these cells.  
2 CB2 modulates immune cell migration both within and outside the central nervous system<sup>25,26</sup>

### 3 4 *Endocannabinoids*

5  
6 In parallel with the discovery of cannabinoid receptors, endogenous substances that bind and  
7 activate these receptors were identified (endocannabinoids). The two best characterized are  
8 arachidonoyl ethanoamide (AEA or anandamide) and 2-arachidonoylglycerol (2-AG), although  
9 other putative endocannabinoids also have been identified. In contrast to conventional  
10 neurotransmitters, endocannabinoids are not stored in synaptic vesicles, but are produced on  
11 demand via cleavage of membrane lipid precursors and then released after *de novo* synthesis.<sup>27,28</sup>  
12 Once formed in response to presynaptic depolarization, endocannabinoids function as “retrograde”  
13 messengers, diffusing back across the synapse and signaling the presynaptic (upstream) neuron to  
14 decrease neurotransmitter release and/or activity. These effects have been implicated in the  
15 modulation of both short- and long term synaptic plasticity, events which are integral to the  
16 remodeling of synaptic networks in the CNS, as well as fundamental processes such as learning  
17 and memory.

18  
19 Termination of the action of AEA and 2-AG is accomplished by re-uptake into the neuron and  
20 subsequent enzymatic degradation. These transport proteins and degradative enzymes represent  
21 other targets for manipulating the endocannabinoid system.

22  
23 AEA primarily activates CB1 receptors, and also stimulates TRPV1 receptors.<sup>29</sup> The latter is an  
24 important component of pain signaling pathways. AEA is a partial or full agonist at CB1 receptors,  
25 depending on the species, tissue, and biological response being examined.<sup>29</sup> Partial agonists are  
26 capable of binding to a receptor, but do not cause maximal activation. Pharmacologically, they can  
27 function as agonists or antagonists, depending on the dose, and endogenous activity of the  
28 biological system they are interacting with. This fact complicates the interpretation of  
29 endocannabinoid effects that have been observed in animal models, as well as findings which may  
30 be relevant to phytocannabinoids such as THC. Although AEA binds to CB2 receptors, it has a  
31 low efficacy, and may act primarily as an antagonist.<sup>29</sup> 2-AG has approximately equivalent activity  
32 at CB1 and CB2 receptors, is much more abundant than AEA in the brain, and is believed to act  
33 primarily as an agonist at cannabinoid receptors.<sup>30</sup> Other putative endocannabinoids also tend to be  
34 considerably more active as CB1 receptor agonists.<sup>31</sup> Additionally, other receptor systems appear  
35 to respond to endocannabinoids.<sup>31,32</sup>

36  
37 THC is also a partial agonist at the CB1 and CB2 receptors. Cannabidiol displays anti-oxidant  
38 activity, is a TRPV1 agonist like AEA, and inhibits the uptake and metabolism of AEA. It has low  
39 efficacy for CB1 and CB2 receptors.

40  
41 Taken together, the endocannabinoid system is widely dispersed and it modulates the activity of  
42 several prominent neurotransmitters, immune regulating cells, and other tissue and organs.  
43 Accordingly, endocannabinoids likely play a role in the regulation of a wide variety of functions  
44 and disease states. Some of the most prominent include appetite regulation, peripheral energy  
45 metabolism, obesity and associated metabolic abnormalities, pain and inflammation,  
46 gastrointestinal motility and secretion, central nervous system disorders,  
47 neurotoxicity/neuroinflammation/neuroprotection, and certain mental disorders, including  
48 substance misuse.<sup>32-38</sup>

1 STATE MEDICAL CANNABIS LAWS

2  
3 Thirteen states (Alaska, California, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New  
4 Mexico, Oregon, Rhode Island, Vermont, and Washington) have enacted laws since 1996 which  
5 remove state-level criminal penalties for qualifying patients (with physician recommendations or  
6 certifications) for cultivation, possession, and use of cannabis.<sup>39</sup> Most of these measures were  
7 adopted by ballot initiative, but some have been passed by state legislatures. Typically, these laws  
8 identify a number of “qualifying conditions.” In California vagaries such as the presence of a  
9 “debilitating condition” or “chronic ailment” or any *other illness for which marijuana provides*  
10 *relief* are introduced. Most state laws provide a specific allowance for cannabis possession, and a  
11 few require/maintain registries or offer certification cards which may assist patients if they are  
12 confronted by police officers.

13  
14 Two other state laws address medical marijuana to a lesser extent. Maryland’s law does not create  
15 a medical marijuana program but protects patients from jail time for possession of marijuana if they  
16 can prove in court that their use of marijuana was a medical necessity; the maximum penalty is a  
17 \$100 fine. Arizona allows physicians to prescribe marijuana, but such a system is not in place  
18 since federal law prohibits physicians from prescribing Schedule I substances. At least 13 other  
19 states have pending legislation or ballot measures to legalize medical marijuana.<sup>40</sup>

20  
21 The number of patients who use cannabis in states that have removed state-level penalties and  
22 permit medical use is not clearly established. According to one compilation, approximately 7,000  
23 physicians have authorized the use of cannabis for at least 400,000 patients.<sup>41</sup>

24  
25 FEDERAL POLICIES

26  
27 *Controlled Substances Act*

28  
29 As recreational drug use proliferated during the 1960s, legislative concern led to passage of the  
30 Comprehensive Drug Abuse Prevention and Control Act of 1970 (commonly referred to as the  
31 Controlled Substances Act). This Act classifies certain psychoactive drugs into 5 categories, or  
32 schedules that impose varying restrictions on access to the drugs under direction of the DEA.

33  
34 A drug is placed in Schedule I if (1) it has a high potential for abuse; (2) it has no currently  
35 accepted medical use in treatment in the United States; and (3) there is a lack of accepted safety for  
36 use of the drug under medical supervision. In contrast, Schedule II criteria are that the drug (1) has  
37 a high potential for abuse; (2) has a currently accepted medical use in treatment in the United States  
38 or a currently accepted medical use with severe restrictions; and (3) abuse of the drug may lead to  
39 severe psychological or physical dependence.

40  
41 Marijuana and tetrahydrocannabinols naturally contained in the cannabis plant (as well as synthetic  
42 equivalents and derivatives with similar activity) are assigned by statute to Schedule I, along with  
43 many other drugs such as heroin, lysergic acid diethylamide (LSD), mescaline and other  
44 hallucinogenic amphetamine derivatives, methaqualone, and illicit fentanyl derivatives. Certain  
45 other psychoactive botanical substances (e.g., peyote, psilocybin) also are in Schedule I. With  
46 regard to the placement of marijuana in Schedule I, the following definition is applied:

47  
48 The term "marihuana" means all parts of the plant *Cannabis sativa*, whether growing or not;  
49 the seeds thereof; the resin extracted from any part of such plant; and every compound,  
50 manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin. Such term  
51 does not include the mature stalks of such plant, fiber produced from such stalks, oil or cake

1 made from the seeds of such plant, any other compound, manufacture, salt, derivative,  
2 mixture, or preparation of such mature stalks (except the resin extracted there from), fiber, oil,  
3 or cake, or the sterilized seed of such plant which is incapable of germination (21 U.S.C. 802).  
4

5 Some botanical products that serve as raw materials (i.e., coca leaves; raw opium, opium poppy  
6 and poppy straw) for controlled substances are themselves placed in Schedule II. These raw  
7 materials are imported into the U.S. from other countries under international treaty and convention.  
8 FDA-approved pharmaceutical preparations containing THC are in Schedule III, whereas a  
9 synthetic analogue (nabilone) is in Schedule II. Schedule III criteria are that the drug (1) has less  
10 potential for abuse than drugs or other substances in schedules I and II; (2) has a currently accepted  
11 medical use in treatment in the United States; and (3) abuse of the drug or other substance may lead  
12 to moderate or low physical dependence or high psychological dependence.  
13

#### 14 *Federal Court Cases Relevant to Medical Marijuana*

15

16 Three prominent federal court cases evolved out of California's 1996 passage of its medical  
17 marijuana ballot initiative (Proposition 215).  
18

19 *Conant v. Walters* (2002). After California passed its medical marijuana regulation in 1996, Barry  
20 R. McCaffrey, Director of the Office of National Drug Control Policy (ONDCP) issued a statement  
21 entitled "The Administration's Response to the Passage of California Proposition 215 and Arizona  
22 Proposition 200." This statement threatened physicians who recommended marijuana with the loss  
23 of their license to prescribe controlled substances and the ability to participate in Medicaid and  
24 Medicare. Physicians and patients filed a class action lawsuit, claiming a constitutional free-speech  
25 right, in the context of a doctor-patient relationship. In *Conant v. Walters* the United States Court  
26 of Appeals in a permanent injunction recognized that physicians have a constitutionally-protected  
27 right to discuss the use of marijuana as a treatment option with their patients and to make oral or  
28 written recommendations for medical marijuana (the AMA had already endorsed this view).<sup>42</sup>  
29 However, the court cautioned that physicians could exceed the scope of this constitutional  
30 protection if they conspire with, or aid and abet, their patients in obtaining medical marijuana. The  
31 U.S. Supreme Court denied the appeal.  
32

33 *USA v. Oakland Cannabis Buyer's Cooperative (OCBC) and Jeffrey Jones* (2001). A medical  
34 cannabis buyer's cooperative was established in Oakland (Oakland Cannabis Buyer's Cooperative).  
35 Its proprietor (Jeffrey Jones) distributed marijuana based on the theory that the cooperative could  
36 operate as each patient's "caregiver" and use a medical necessity defense. The U.S. government  
37 disagreed and the Department of Justice filed a civil suit in January 1998 to close six medical  
38 marijuana distribution centers in northern California. Ultimately, the case went to the U.S.  
39 Supreme Court which ruled unanimously that a medical necessity exception for marijuana was at  
40 odds with the terms of the Controlled Substances Act (i.e., the CSA classified marijuana as lacking  
41 a recognized medical benefit).<sup>43</sup>  
42

43 *Gonzales v. Raich* (2005). In response to DEA agents' destruction of their cannabis plants, two  
44 patients and caregivers in California brought suit. They argued that applying the CSA to a situation  
45 in which cannabis was being grown and used locally for medicinal purposes (and not being sold)  
46 exceeded the federal government's constitutional authority under the Commerce Clause, which  
47 allows federal regulation of interstate commerce. The U.S. Supreme Court eventually ruled that  
48 Congress's power to regulate commerce "extends to purely local activities" that are "part of an  
49 economic class of activities that have a substantial effect on interstate commerce."<sup>44</sup> While not  
50 invalidating state medical marijuana laws, this ruling preserved the ability of the DEA to enforce  
51 the CSA against medical marijuana patients and their caregivers.



1 Another relevant case is the *County of San Diego v. State of California* (2009) in which the U.S.  
2 Supreme Court denied an appeal by the County of San Diego allowing a lower court's ruling to  
3 stand which held that federal law does not preempt California's medical marijuana law. The  
4 County had argued that it did not have to comply with the state-mandate to implement an  
5 identification card program for patients based on federal preemption.  
6

7 Accordingly, states can create medical marijuana laws protecting patients and caregivers from  
8 prosecution under their own state-level controlled substance laws, but federal agents can still  
9 investigate, arrest, and prosecute medical marijuana patients, caregivers, and physicians (if they  
10 willfully aid and abet) in such states.

## 11 12 RESCHEDULING

### 13 14 *Efforts to Remove Marijuana from Schedule I*

15  
16 Advocates of decriminalizing marijuana have attempted to have it removed from Schedule I ever  
17 since its original placement. A petition was first filed in 1972 by the National Organization for the  
18 Reform of Marijuana Laws (NORML) to the Bureau of Narcotics and Dangerous Drugs seeking to  
19 reschedule marijuana to Schedule II. After this petition was denied and public hearings were not  
20 conducted, NORML filed suit in 1974 against the Bureau and in 1975 against its successor, the  
21 DEA. After further legal maneuvering, the petition was eventually sent back to the DEA for  
22 consideration in 1980 by the U.S. Court of Appeals for the District of Columbia. Eventually,  
23 public hearings were held over a 2-year period from 1986 to 1988, at which time the DEA  
24 Administrator once again rejected the position of NORML (now joined by the Alliance for  
25 Cannabis Therapeutics [ACT], the Drug Policy Foundation, and the Physicians Association for  
26 AIDS Care, among others) despite recommendations to the contrary by the DEA administrative  
27 law judge in the case which called for reclassification of marijuana to Schedule II. The latter  
28 parties petitioned the District Court for review of this order; after once again remanding the case in  
29 1991, the District Court denied the petition for review on February 18, 1994. Subsequent  
30 rescheduling petitions also have been rejected.  
31

32 Although the petition for review was denied, it led to a revised formulation by the DEA for  
33 determining whether a drug has a "currently accepted medical use." The 5-part test for fulfilling the  
34 accepted medical use criteria of Schedule II is now comprised of the following:  
35

- 36 • the drug's chemistry must be known and reproducible;
- 37 • there must be adequate safety studies;
- 38 • there must be adequate and well-controlled studies proving efficacy;
- 39 • the drug must be accepted by qualified experts; and
- 40 • the scientific evidence must be widely available.

41  
42 A drug must meet all 5 criteria to be considered for rescheduling by the DEA.  
43

44 Even if marijuana were rescheduled under current law it could not be marketed or medically  
45 available for general prescription use unless it was reviewed and approved by FDA under the  
46 Federal Food, Drug, and Cosmetic Act (FFDCA) (see below). Conceivably, a physician may be  
47 able to write a prescription for an individual patient with the cooperation of a compounding  
48 pharmacist with a schedule II license. However, the FDA treats compounded products as "new  
49 drugs" subject to all the requirements of the FFDCA if pharmacists attempt to compound large  
50 quantities of medication.

1 Congress or the Executive branch (through regulatory procedures authorized by the CSA) could  
 2 reschedule marijuana. Over the last decade various federal amendments (e.g., Hinchey-  
 3 Rohrabacher) have been submitted that would prevent the Justice Department from using  
 4 appropriated funds to interfere with the implementation of medical cannabis laws, and bills have  
 5 been introduced that would reschedule marijuana and/or prevent provisions of the CSA and  
 6 FFDCa from restricting activities in states that have adopted medical marijuana programs. These  
 7 have all been defeated to date, but others are pending.

8  
 9 *“Executive Order”*

10  
 11 Resolution 229 (A-09) makes reference to a “Presidential/Executive” order. To the Council’s  
 12 knowledge no such order exists. As previously mentioned, in 1996, the Director of ONDCP issued  
 13 a statement that threatened physicians with loss of certain privileges. However, this was not an  
 14 Executive Order, but rather a compilation of strategies developed by several federal agencies. It  
 15 never had the force of an Executive Order, and is nonetheless moot because of the permanent  
 16 injunction issued against implementation of this strategy in *Conant v. Walters*.

17  
 18 During the 2008 Presidential campaign, then-Senator Obama pledged to avoid the use of federal  
 19 resources in cracking down on medical marijuana activities in states where medical marijuana laws  
 20 were in place. This view has since been reiterated by the Attorney General in press briefings,  
 21 although DEA raids on a medical marijuana dispensaries in California have occurred in the same  
 22 time frame. Resolution 229 (A-09) was prompted by pending medical marijuana legislation in the  
 23 state of New York, and perhaps a provision authored by Congressman Maurice Hinchey (D-NY)  
 24 that seeks to clarify the Obama administration’s medical marijuana enforcement policy. The  
 25 Hinchey provision was included in the report accompanying the Commerce, Justice, Science and  
 26 related Agencies appropriation bill for fiscal year 2010. The provision (referring to the Department  
 27 of Justice) reads:

28  
 29 “There have been conflicting public reports about the Department’s enforcement of medical  
 30 marijuana policies. Within 60 days of enactment, the Department shall provide to the  
 31 Committee clarification of the Department’s policy regarding enforcement of federal laws and  
 32 use of federal resources against individuals involved in medical marijuana activities.”

33  
 34 **CONDUCTING CLINICAL RESEARCH ON SCHEDULE I VS SCHEDULE II COMPOUNDS**

35  
 36 Researchers who propose to conduct investigations in humans on Schedule I drugs must obtain  
 37 FDA review of the protocol and fulfill the FDA’s Investigational New Drug (IND) requirements  
 38 for safety. They also must submit the protocol to the DEA as part of the process to obtain a valid  
 39 registration for a Schedule I substance. When DEA receives the Schedule I research application,  
 40 they forward it to another division within FDA for scientific review as part of their decision-  
 41 making process. Investigators conducting research with a Schedule I substance must submit a  
 42 protocol for each study involving each Schedule I substance to obtain approval to conduct that  
 43 research. If a new protocol for a research study, even with the same substance is devised, the DEA  
 44 registration must be amended by submitting the new protocol for review to the DEA. This is a  
 45 requirement under the CSA and is separate from the FFDCa requirements for submitting INDs for  
 46 human studies to the FDA, whereby FDA assesses whether the study design is safe.

47  
 48 Investigators seeking to do human research on Schedule II substances must still procure FDA  
 49 safety review of the protocol and apply for a Schedule II registration with the DEA. Once granted,  
 50 this Schedule II license is sufficient for all future studies on that substance.

1 The only legal federal source of marijuana is grown under the auspices of the National Institute on  
2 Drug Abuse (NIDA), and prior to 1999 only NIH-funded studies on marijuana could qualify for  
3 access to the NIDA supply. In May 1999, the Department of Health and Human Services  
4 announced a new guidance on procedures for the provision of marijuana for medical purposes on a  
5 cost-reimbursable basis.<sup>45</sup> For protocols submitted by non-NIH funded sources, institutional peer  
6 review and IRB approval precede the submission, after which the scientific merits of each protocol  
7 are evaluated through a Public Health Service interdisciplinary review process. This guidance  
8 created an avenue for externally funded investigators to acquire marijuana for research purposes,  
9 but retains additional review and approval steps that are not required of other traditional IND-  
10 sponsors.

11

12 In an effort to promote research on medical cannabis, California's State Assembly appropriated \$3  
13 million to establish a university-based Center for Medicinal Cannabis Research, to be administered  
14 jointly by the University of California's San Diego and San Francisco campuses.<sup>46</sup> Subsequently,  
15 many of the randomized controlled trials on smoked cannabis have been supported by this  
16 program. The cannabis used in such studies is obtained from NIDA in accordance with the  
17 procedures outlined above.

18

## 19 BOTANICALS AS DRUG PRODUCTS

20

21 Many drugs have been derived from plants, and the *National Formulary* and *U.S. Pharmacopoeia*  
22 formerly contained numerous botanical agents. Interest in the use of such agents waned with  
23 advances in the understanding of physiologic, biochemical, and cellular functioning.  
24 Pharmaceutical development evolved with a focus on identifying specific cellular targets  
25 (receptors) amenable to drug intervention, although plants may provide the starting material for  
26 certain products. The 1994 passage of the Dietary Supplement and Health Education Act fostered  
27 a return to the public's use of botanical products in the form of "dietary supplements." Such  
28 products are regulated as foods, and are not subject to FDA approval for safety and efficacy. They  
29 can use so called "structure and function" claims but cannot claim to be useful in the treatment of a  
30 disease or condition. In order to make a disease-based claim, the product must go through the FDA  
31 drug approval process.

32

33 In 2004, the FDA issued a *Guidance for Industry Botanical Drug Products* monograph.<sup>47</sup> This  
34 document provides the pathway by which botanical agents can be approved as prescription drugs.  
35 The crude botanical substance can become a "botanical drug substance" through processes of  
36 extraction, blending, addition of excipients, formulation, and packaging in a defined manner.  
37 Particular attention is devoted to product composition because botanicals are complex mixtures of  
38 chemical/structural components. Similar to conventional products, a botanical drug substance must  
39 undergo animal toxicity studies, and demonstrate its safety and efficacy in randomized, double-  
40 blind, placebo-controlled trials. Additional pharmacologic and toxicologic studies are required if a  
41 non-oral route (e.g., inhalation) of administration is contemplated. If the substance is intended to  
42 treat chronic conditions, 6 to 12 months in long-term safety extension studies is considered  
43 sufficient.

44

45 An example of a drug that is seeking FDA approval through this pathway is an extract prepared  
46 from two different breeds of cannabis that have been genetically developed to produce either high  
47 quantities of THC or cannabidiol. Chemovars of cannabis were selected via Mendelian genetics to  
48 express one predominant phytocannabinoid. Cloned plants undergo extraction to produce botanical  
49 drug substances that contain predominately THC or cannabidiol, or an approximate 1:1  
50 combination of the two. The final product is a botanical extract (Nabiximols) comprising an  
51 oromucosal spray that delivers 2.7 mg of THC and 2.5 mg of cannabidiol per spray. Patients self-

1 titrate their overall dose and pattern of dosing according to their response and tolerance of the  
2 medicine. This botanical drug substance is approved in Canada (Sativex®) for the symptomatic  
3 relief of neuropathic pain in patients with multiple sclerosis, and as an adjunctive analgesic to  
4 opioids in patients with advanced cancer pain.<sup>48-50</sup> Nabiximols is progressing through the FDA  
5 pathway for botanical drug substance approval as a treatment for patients with advanced cancer  
6 whose pain has not been adequately relieved by optimized treatment with opioid medications.

7  
8 Other cannabinoid based botanical drug substances have been developed in other countries (e.g.,  
9 Cannador®), and several are in development in the U.S. with various modes of action (botanical  
10 extracts; CB receptor agonists or antagonists; inhibitors of endocannabinoid uptake or  
11 degradation). Cannador® is an extract delivered in an oral dosage form containing primarily 2.5  
12 mg THC and 1 mg cannabidiol. It has demonstrated benefit in randomized controlled trials  
13 involving patients with multiple sclerosis experiencing pain due to spasm, and in decreasing post-  
14 operative pain.<sup>51,52</sup> The development of pharmaceutical grade cannabis-based extracts with proven  
15 medical benefits provides further evidence on the therapeutic potential of components of the  
16 cannabis plant.

## 17 18 SMOKED CANNABIS STUDIES

19  
20 Currently cannabinoids are “available” in three different categories:<sup>41</sup> FDA approved oral  
21 preparations of THC (Dronabinol; Marinol®) and a synthetic analogue (Nabilone; Cesament®);  
22 *Cannabis sativa* extracts (e.g., Nabiximols [Sativex®], [Cannador®]) not currently approved in the  
23 U.S.; and crude botanical sources made available under state laws. Since 2001, systematic reviews  
24 have been conducted on smoked cannabis and other cannabinoids (mostly oral THC and botanical  
25 extracts).<sup>53-56</sup> The following discussion focuses on randomized, placebo-controlled human trials  
26 that have evaluated smoked cannabis. Table 1 summarizes the characteristics and findings of such  
27 trials.

### 28 29 *Randomized Trials on Smoked Cannabis*

30  
31 Cancer chemotherapy. Three randomized, double-blind, controlled trials involving a total of 43  
32 patients have evaluated the efficacy of smoked cannabis to alleviate nausea and vomiting  
33 accompanying cancer chemotherapy; one directly compared smoked cannabis with oral THC but  
34 was never published in a peer reviewed journal.<sup>57-59</sup> These trials revealed a modest antiemetic  
35 effect of smoked cannabis greater than placebo.

36  
37 Several research/treatment studies were conducted by state departments of health during the late  
38 1970s and early to mid-1980s under protocols approved by the FDA. These open label studies  
39 involved patients who had responded inadequately to other antiemetics. In such patients, smoked  
40 cannabis was reported to be comparable to or more effective than oral THC, and considerably more  
41 effective than prochlorperazine or other previous antiemetics in reducing nausea and emesis.  
42 Results of these studies generally were based on patients’ and/or physicians’ subjective ratings.  
43 These programs were noted in the 1997 Council report and another independent review that was  
44 published in 2001.<sup>56</sup> Smoked cannabis (as well as THC and other synthetic cannabinoids) is more  
45 effective than older antiemetic drugs (neuroleptics) and placebo.<sup>53</sup> All of these trials in cancer  
46 patients were conducted before the advent of 5-HT<sub>3</sub> and neurokinin-1 receptor antagonists.  
47 Smoked cannabis has been compared with the 5-HT<sub>3</sub> receptor antagonist ondansetron in an  
48 experimental emesis model. This randomized double-blind included 13 healthy volunteers who  
49 received syrup of ipecac.<sup>60</sup> Smoked cannabis significantly reduced ratings of queasiness and  
50 slightly reduced the vomiting induced by the syrup compared with placebo. Ondansetron  
51 completely eliminated episodes of vomiting.

1 Appetite stimulation. Three randomized, placebo-controlled trials involving a total of 97 HIV+  
2 adult patients have compared the effects of smoked cannabis with oral THC or dronabinol; two  
3 used a “within subjects” design. Generally, the effects of smoked cannabis (2% or 3.9% THC)  
4 were comparable to oral cannabinoids in increasing caloric intake and triggering weight gain,  
5 although the dose of oral THC was substantially higher than normally recommended.<sup>61-63</sup> HIV viral  
6 load and the pharmacokinetics of concurrent protease inhibitors were unaffected over a three week  
7 period.<sup>61</sup>

8  
9 Pain Management. Two randomized, double-blind, placebo-controlled trials involving a total of  
10 89 patients with HIV-associated peripheral neuropathy, and one (n = 38) involving an experimental  
11 pain model (capsaicin) have been reported.<sup>64,65</sup> The latter was a randomized, double-blind,  
12 placebo-controlled crossover trial in 15 healthy volunteers examining the effects of cannabis  
13 cigarettes (2%, 4%, or 8%) on pain and cutaneous hyperalgesia induced by intradermal capsaicin.<sup>65</sup>  
14 The medium dose exhibited delayed analgesia, significantly inhibiting capsaicin-induced pain at 45  
15 minutes after drug exposure; the low dose was ineffective, and the high dose increased capsaicin-  
16 induced pain at 45 minutes. Smoked cannabis did not significantly affect acute painful heat, cold,  
17 and mechanical thresholds.<sup>64</sup>

18  
19 In patients with HIV-associated neuropathic pain, cannabis cigarettes of varying concentration and  
20 number consumed over a 5-day period significantly reduced pain intensity. Approximately half of  
21 patients experienced more than a 30% reduction, which is a standard benchmark for efficacy.  
22 Analysis of the number-needed-to-treat also compared favorably with historic values associated  
23 with other drugs used to treat neuropathic pain.<sup>66,67</sup>

24  
25 Generally, side effects typically attributable to THC (anxiety, sedation, confusion, dizziness,  
26 fatigue, tachycardia, dry mouth) were noticeable in these studies but were tolerable and not  
27 considered dose-limiting. The use of higher potency cigarettes was more likely to be associated  
28 with drug-related cognitive decline on psychological testing.

29  
30 The overall evaluation of the clinical effects of smoked cannabis in stimulating appetite and  
31 relieving neuropathic pain (and to a certain degree, nausea) correlates with patterns of use reported  
32 in surveys of HIV+ patients. In this population, cannabis use also has been associated with  
33 adherence to antiretroviral therapy in patients who experience nausea, and for the self management  
34 of HIV-associated peripheral neuropathy.<sup>68,69</sup> In one consecutive series, 23% of HIV+ patients  
35 reported smoking cannabis in the prior 30 days to improve appetite or relieve pain, but also to  
36 relieve anxiety or depression or “increase pleasure” which are characteristics of substance misuse  
37 or recreational use.<sup>70</sup> Another survey found a similar percentage of HIV-positive patients (27%)  
38 used cannabis to improve appetite, relieve nausea and pain, and for anxiety and depression. Nearly  
39 half of these users reported memory deterioration.<sup>71</sup>

40  
41 Multiple Sclerosis and Spasticity. Surveys reveal that 36% to 68% of patients with multiple  
42 sclerosis have experimented with smoked cannabis for symptom relief, and approximately 15% are  
43 continuing users.<sup>72,73</sup> Two randomized, double-blind, placebo-controlled trials involving a total of  
44 40 patients have been reported in patients with multiple sclerosis and spasticity.<sup>74,75</sup> In a pilot study  
45 involving 10 patients who smoked one cannabis cigarette of low potency (1.54% THC) some  
46 patients reported subjective improvements, but exhibited impairment of posture and balance.<sup>74</sup>  
47 When higher potency cannabis cigarettes were used for three days, reduced scores for pain (50%)  
48 and spasticity (30%) were observed, along with some cognitive impairment, dizziness, and fatigue;  
49 the majority of these patients had prior experience smoking cannabis.<sup>75</sup>

1 Glaucoma. In one randomized, double-blind, placebo-controlled crossover study of 18 adults with  
2 glaucoma, smoking one cannabis cigarette (2% THC) caused a significant reduction in intraocular  
3 pressure, along with alterations in sensory perception, tachycardia/palpitations, and postural  
4 hypotension.<sup>76</sup>

## 5 6 ADVERSE EFFECTS OF SMOKED CANNABIS

7  
8 Determining the adverse effects of smoked cannabis used as medicine is problematic since only  
9 short-term controlled trials have been conducted. Most research on the harmful consequences of  
10 cannabis use has been conducted in simulated laboratory environments and in individuals who use  
11 cannabis for nonmedical purposes. One independent health assessment of four of the remaining  
12 seven patients obtaining cannabis cigarettes through the federal government's Compassionate Use  
13 Treatment IND (see Council report from 1997),<sup>1</sup> showed no demonstrable adverse outcomes  
14 related to their chronic medicinal cannabis use. Some of cannabis' adverse effects differ in  
15 experienced versus inexperienced users, and it is not clear to what extent the adverse effects  
16 reported in recreational users are applicable to those who use cannabis for the self-management of  
17 disease or symptoms. Most data on adverse effects has come from observational population-based  
18 cohort studies of recreational cannabis users, an unknown portion of whom may be using the  
19 substance for medicinal purposes. Adverse reactions observed in short-term randomized, placebo-  
20 controlled trials of smoked cannabis to date are mostly mild without substantial impairment. A  
21 systematic review of the safety studies on medical cannabinoids published over the last 40 years  
22 (not including studies on smoked cannabis) found that short term use was associated with a number  
23 of adverse events, but less than 4% were considered serious.<sup>77</sup>

### 24 25 *Nonmedical Use*

26  
27 Nonmedical use of marijuana continues to be problematic in society. Approximately one third of  
28 all Americans over 12 years of age have tried marijuana, usually experimenting first during  
29 adolescence.<sup>4</sup> According to the most recent NSDUH Survey, marijuana continues to be the most  
30 commonly used illicit drug (14.4 million past month users).<sup>78</sup> Among persons aged 12 or older, the  
31 rate of past month marijuana use in 2007 (5.8 percent) was similar to the rate in 2006 (6.0 percent).  
32 The prevalence of past month marijuana use among adolescents (i.e., youths aged 12 to 17)  
33 generally decreased from 2002 (8.2 percent) to 2005 (6.8 percent), and then remained constant  
34 between 2005 and 2007. Adolescents who perceived great risk from smoking marijuana once a  
35 month were much less likely to have used marijuana in the past month than those who perceived  
36 moderate to no risk (1.4 vs. 9.5 percent). The specific illicit drugs that had the highest levels of  
37 past year dependence or abuse in 2007 were marijuana (3.9 million), followed by pain relievers  
38 (1.7 million) and cocaine (1.6 million). It is not clear how any of these trends have been influenced  
39 by the medical cannabis debate.

40  
41 Acutely, smoked cannabis increases heart rate, and blood pressure may decrease on standing.  
42 Cannabis intoxication is associated with impairment of short-term memory, attention, motor skills,  
43 reaction time, and the organization and integration of complex information.<sup>1</sup> Although dependent  
44 on the setting, smoked cannabis can cause relaxation and enhance mood. However, some  
45 individuals experience acute anxiety or panic reactions, confusion, dysphoria, paranoia, and  
46 psychotic symptoms (e.g., delusions, hallucinations).<sup>1</sup>

### *Substance Dependence*

Chronic cannabis use is associated with development of tolerance to some effects and the appearance of withdrawal symptoms (restlessness, irritability, mild agitation, insomnia, sleep disturbances, nausea, cramping) with the onset of abstinence. Depending on the measures and age group studied, 4% to 9% of cannabis users fulfill diagnostic criteria for substance dependence. Although some cannabis users develop dependence, they are considerably less likely to do so than users of alcohol and nicotine, and withdrawal symptoms are less severe.<sup>4,79,80</sup> Like other drugs, dependence is more likely to occur in individuals with co-morbid psychiatric conditions.

Whether or not cannabis is a “gateway” drug to other substance misuse is controversial and whether the medical availability of cannabis would increase drug abuse is not known. Analysis of trends in emergency room visits for marijuana do not support the view that state authorization for medical cannabis use leads to increased signals of substance misuse.<sup>81</sup> The IOM concluded that marijuana use is not the cause or even the most serious predictor of serious substance use disorders.<sup>4</sup> A systematic review of longitudinal studies on the use of cannabis concluded its use was consistently associated with reduced educational achievement and the use of other drugs, but not other measures of psychosocial harm.<sup>82</sup>

### *Cognitive Deficits and Mental Health*

Other concerns about long-term cannabis use include cognitive effects, and its intersection with mental disorders. Acute intoxication with cannabis causes marked changes in subjective mental status, brain functioning, and neuropsychological performance. A meta-analysis conducted in 2003 found evidence of subtle impairments in the ability to learn and remember new information in chronic cannabis smokers, but no general persistent neuropsychological deficits.<sup>83</sup> Neuropsychological deficits and differences in brain functioning are most consistently observed among frequent, heavy users.<sup>84</sup>

A recent systematic review on cannabis use and the risk of psychotic or affective mental health outcomes renewed the debate about the potential role of smoked cannabis as a cause or sequelae of mental disorders.<sup>85</sup> Whether cannabis use contributes to mental disorders, is used for self-management of mental disorders, or the mental disorder itself lends to cannabis use is not clear. The recent discontinuation of clinical trials on a CB1 receptor antagonist because of suicidal ideation indicates some involvement of endocannabinoids in the regulation of mood.

### *Respiratory Illness and Cancer*

Like tobacco, chronic cannabis smoking is associated with markers of lung damage and increased symptoms of chronic bronchitis.<sup>86-88</sup> However, results of a population-based case control study of cannabis smokers found no evidence of increased risk for lung cancer or other cancers affecting the oral cavity and airway.<sup>89</sup> Another population-based case-control study of marijuana use and head and neck squamous cell carcinoma (HNSCC) concluded that moderate marijuana use is associated with reduced risk of HNSCC.<sup>90</sup> Furthermore, although smoking cannabis and tobacco may synergistically increase the risk of respiratory symptoms and COPD, smoking only cannabis is not associated with an increased risk of developing COPD.<sup>91</sup> One recent study suggests that use of smoked cannabis is associated with an increased risk for testicular cancers.<sup>92</sup>

The use of a vaporizing device may mitigate some of these symptoms. Cannabis vaporization is a technique aimed at suppressing the formation of irritating respiratory toxins by heating cannabis to a temperature where active cannabinoids are volatilized, but below the point of combustion where

1 smoke and associated toxins form. The use of a vaporizer is associated with higher plasma THC  
2 concentrations than smoking marijuana cigarettes, little if any carbon monoxide production, and  
3 significantly fewer triggered respiratory symptoms.<sup>93,94</sup>

#### 4 5 *Immunosuppression*

6  
7 Cannabinoids exert immunosuppressive and anti-inflammatory effects.<sup>95-97</sup> Plant-derived and  
8 synthetic cannabinoids exert antiproliferative effects on a wide spectrum of human tumor cell lines  
9 in culture, although mitogenic responses also have been observed.<sup>98,99</sup> Apoptosis, inhibition of  
10 proliferation, suppression of cytokine and chemokine product and induction of T regulatory cells  
11 have been identified. CB2 receptors are associated with activated microglia in the CNS.<sup>100</sup>  
12 Clearly endocannabinoids are immune modulators, but how they regulate various elements of the  
13 human immune response is unclear, and how exogenous cannabinoids may interact with these  
14 processes also is not established. Short-term use of smoked cannabis did not affect viral load in  
15 HIV-positive patients and also is associated with adherence to therapy and reduced viral loads in  
16 patients with hepatitis C infections.<sup>61,101</sup>

#### 17 18 SUMMARY AND CONCLUSION

19  
20 Despite more than 30 years of clinical research, only a small number of randomized, controlled  
21 trials have been conducted on smoked cannabis. These trials were short term and involved a total  
22 of ~300 patients. Results of these trials indicate smoked cannabis reduces neuropathic pain,  
23 improves appetite and caloric intake especially in patients with reduced muscle mass, and may  
24 relieve spasticity and pain in patients with multiple sclerosis. Substantially better alternatives than  
25 smoked cannabis are available to treat patients with glaucoma or chemotherapy-induced nausea  
26 and vomiting. Smoked cannabis has not been subject to any sort of rigorous study in any other  
27 indication. Results obtained from oral cannabinoid products (including botanical extracts) are not  
28 directly applicable to smoked cannabis for a number of reasons including substantial differences in  
29 constituents, pharmacokinetics of active ingredients, and active metabolite patterns. However,  
30 development of botanical extracts as prescription medications lends further credence to the  
31 therapeutic potential of components of the cannabis plant.

32  
33 There is a contrast between the relatively small number of patients who have been studied over the  
34 past 30 years in controlled clinical trials involving smoked cannabis and survey data from patients  
35 with chronic pain, multiple sclerosis, and amyotrophic lateral sclerosis that indicates a significant  
36 use of cannabis for self management. Additionally, surveys of patients with HIV or hepatitis C  
37 infection suggest that smoked cannabis is used to relieve a constellation of symptoms (pain,  
38 nausea, appetite suppression, sleep disorders) and as a source of palliation from antiviral  
39 medication side effects.

40  
41 Marijuana is the most common illicit drug used by the nation's youth and young adults. However,  
42 the fact that cannabis is prone to nonmedical use does not obviate its potential for medical product  
43 development. Many legal pharmaceutical products that are used for pain relief, palliation, and  
44 sleep induction have more serious acute toxicities than marijuana, including death. Witness the  
45 evolving series of steps that the FDA has taken in recent months to address the inappropriate use  
46 and diversion of certain long-acting Schedule II opioid drugs. However, the patchwork of state-  
47 based systems that have been established for "medical marijuana" is woefully inadequate in  
48 establishing even rudimentary safeguards that normally would be applied to the appropriate clinical  
49 use of psychoactive substances. Recent documentaries have noted the ease with which individuals  
50 can "qualify" for access to cannabis products in certain parts of California.



1 The AMA supports the concept of drug approval by scientific and regulatory review to establish  
2 safety and efficacy, combined with appropriate standards for identity, strength, quality, purity,  
3 packaging, and labeling, rather than by ballot initiative or state legislative action. The future of  
4 cannabinoid-based medicine lies in the rapidly evolving field of botanical drug substance  
5 development, as well as the design of molecules that target various aspects of the endocannabinoid  
6 system. To the extent that rescheduling marijuana out of Schedule I will benefit this effort, such a  
7 move can be supported. In the meantime, physicians who comply with their ethical obligations to  
8 “first do no harm” and to “relieve pain and suffering” should be protected in their endeavors,  
9 including advising and counseling their patients on the use of cannabis for therapeutic purposes.

10

11 RECOMMENDATION

12

13 The Council on Science and Public Health recommends that the following statement be adopted in  
14 lieu of Resolutions 910 (I-08), 921 (I-08), and 229 (A-09) and the remainder of the report be filed.

15

16 Our American Medical Association (AMA) urges that marijuana’s status as a federal Schedule  
17 I controlled substance be reviewed with the goal of facilitating the conduct of clinical research  
18 and development of cannabinoid-based medicines. This should not be viewed as an  
19 endorsement of state-based medical cannabis programs, the legalization of marijuana, or that  
20 scientific evidence on the therapeutic use of cannabis meets the current standards for a  
21 prescription drug product. (New HOD Policy)

Fiscal Note: Less than \$500

REFERENCES

1. Council on Scientific Affairs Report 10. Medical marijuana. American Medical Association, Interim Meeting, Dallas, Texas; December 1997.
2. Council on Scientific Affairs Report 6. Medical marijuana. American Medical Association, Annual Meeting, Chicago, Illinois; June 2001.
3. Joy JE, Watson S Jr, Benson JA Jr, eds. *Marijuana and Medicine. Assessing the Science Base*. Division of Neuroscience and Behavioral Health, Institute of Medicine. National Academy Press: Washington, DC; 1999.
4. American College of Physicians. Supporting research into the therapeutic role of marijuana. American College of Physicians; 2008: Position Paper.  
[http://www.acponline.org/advocacy/where\\_we\\_stand/other\\_issues/medmarijuana.pdf](http://www.acponline.org/advocacy/where_we_stand/other_issues/medmarijuana.pdf). Accessed August 8, 2009.
5. O'Shaughnessy WB. On the preparation of the Indian hemp or gunjah (*Cannabis indica*): the effects on the animal system in health and their utility in the treatment of tetanus and other convulsive diseases. *Trans Med Phys Soc Bombay*. 1839;8:421-461.
6. Mikuriya TH, ed. *Marijuana: Medical Papers, 1839-1972*. Oakland, Calif: MediComp; 1973.
7. Reynolds JR. On the therapeutic uses and toxic effects of *Cannabis indica*. *Lancet*. 1890;1:637-638.
8. US Congress, House Ways and Means Committee, Hearings on H.R. 6385: Taxation of Marihuana, 75th Cong, 1st session, April 27, 1937.
9. Report of the Committee on Legislative Activities. *JAMA*. 1937;108:2214-2215.
10. Mechoulam R, Gaoni Y. A total synthesis of d,1-delta-1-tetrahydrocannabinol, the active constituent in hashish. *J Am Chem Soc*. 1965;87:3273-3275.
11. Turner CE, Elsohly MA, Boeren EG. Constituents of *Cannabis sativa*. XVII. A review of natural constituents. *J Nat Prod*. 1980;43:169-234.
12. Isbell H. Clinical pharmacology of marihuana. *Pharmacol Rev*. 1971;23:337-338.
13. Razdan RK. Structure-activity relationships in cannabinoids. *Pharmacol Rev*. 1986;38:75-149.
14. Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animal and humans. *Addiction*. 1996;91:1585-1614.
15. Garrett ER, Hunt CA. Physicochemical properties, solubility, and protein binding of delta9-THC. *J Pharm Sci*. 1974;63:1056-1064.
16. Dewey WL, Martin BR, May EL. Cannabinoid stereoisomers: pharmacologic effects In: Smith DF, ed. *CRC Handbook of Stereoisomers: Drugs in Psychopharmacology*, Boca Raton, FL: CRC Press; 1984:317-326.

17. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. *Nature*. 1990;346:561–564.
18. Biegon A, Kerman IA. Autoradiographic study of pre- and postnatal distribution of cannabinoid receptors in human brain. *Neuroimage*. 2001;14:1463-1468.
19. Glass M, Dragunow M, Faull, R.L. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. *Neuroscience*. 1997;77:299-318.
20. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. *Pharmacol. Rev.* 2002;54:161-202.
21. Mackie K. Signaling via CNS cannabinoid receptors. *Mol Cell Endocrinol*. 2008;286:S60-S65.
22. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. *Nature*. 1993;365:61–65.
23. Onaivi ES, Ishiguro H, Gong JP, et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. *Ann. N. Y. Acad. Sci.* 2006;1074:514-536.
24. Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. *Science*. 2005;310:329-332.
25. Walter L, Stella N. Cannabinoids and neuroinflammation. *Br J Pharmacol*. 2004;141:775–785.
26. Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. *AAPS J*. 2005;7:E625–E654.
27. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science*. 1992;258:1946–1949.
28. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. *Biochem Biophys Res Commun*. 1995;215:89–97.
29. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol Reviews*. 2006;58:389-462.
30. Sugiura T, Waku K. Cannabinoid receptors and their endogenous ligands. *J Biochem*. 2002; 132:7–12.
31. Alexander SPH, Kendall DA. The complications of promiscuity: endocannabinoid action and metabolism. *Brit J Pharmacol*. 2007;152:602-623.
32. Pertwee RG. GPR55: a new member of the cannabinoid receptor clan? *Br J Pharmacol*. 2007;152:984-986.
33. Vemuri VK, Janero DR, Makriyannis A. Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. *Physiol Behav*. 2008;93:671-686.

34. Richardson D, Pearson RG, Kurina N, et al. Characterization of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. *Arthritis Res Ther.* 2008;10(2):R43 (Epub).
35. Wright KL, Duncan M, Sharkey KA. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in sites of inflammation. *Brit J Pharmacol.* 2008;153:263-270.
36. Mangieri RA, Piomelli D. Enhancement of endocannabinoid signaling and the pharmacotherapy of depression. *Pharmacol Res.* 2007;56:360-366.
37. Solinas M, Yasar S, Goldberg SR. Endocannabinoid system involvement in brain reward processes related to drug abuse. *Pharmacol Res.* 2007;56:393-405.
38. Jhaveri MD, Richardson D, Chapman V. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. *Brit J Pharmacol.* 2007;152:624-632.
39. Thirteen legal medical marijuana states. Laws, fees and possession limits. <http://medicalmarijuana.procon.org/viewresource.asp?resourceID=000881>
40. Thirteen states with pending legislation or ballot measures to legalize medical marijuana (as of July 19, 2009). <http://medicalmarijuana.procon.org/viewresource.asp?resourceID=002481>.
41. Aggarwal SK, Carter GT, Sullivan MD, ZumBrunnen C, Morrill R, Mayer JD. Medicinal use of cannabis in the United States. Historical perspective, current trends and future directions. *J Opioid Management.* 2009;5:153-168.
42. Conant v. Walters, 309 F.3d 629 (9th Cir. 2002).
43. USA v. Oakland Buyers Cooperative 532 U.S. 483 (2001).
44. Gonzales v. Raich 545 U.S. 1, (2005).
45. Announcement of the Department of Health and Human Services Guidance on Procedures for Provision of Marijuana for medical Research. <http://grants.nih.gov/grants/guide/notice-files/not99-091.html>.
46. Center for Medical Cannabis Research. University of California. <http://www.cmcr.ucsd.edu/geninfo/research.htm>.
47. US Food and Drug Administration. Guidance for Industry Botanical Drug Products. <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070491.pdf>.
48. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterized by allodynia: a randomized, double blind, placebo-controlled trial. *Pain.* 2007;133:210-220.
49. Rog DJ, Nurimikko TJ, Young CA. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open label, 2-year extension trial. *Clin Ther.* 2007;29:2068-2079.

50. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. *Neurology*. 2005;65:812-819.
51. Holdcroft A, Maze M, Dore C, et al. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. *Anesthesiology*. 2006;104:1040-1046.
52. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomized placebo-controlled trial. *Lancet*. 2003;362:1517-1526.
53. Rocha FC, Stefano SC, de Cassia Haiek R, Rosa Oliveira L, da Silveira D. Therapeutic use of *Cannabis sativa* on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. *Eur J Cancer Care*. 2008;17:431-443.
54. Bagshaw SM. Medical efficacy of cannabinoids and marijuana: a comprehensive review of the literature. *J Palliative Care*. 202;18:111-122
55. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. *J Ethnopharmacology*. 2006;105:1-25.
56. Musty RE, Rossi R. Effects of smoked cannabis and oral  $\Delta^9$ tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: a review of state clinical trials. *J Cannabis Therap*. 2001;1:2956.
57. Chang AE, Shiling DJ, Stillman RC, et al. Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate: a prospective, randomized evaluation. *Ann Intern Med*. 1979;91:819-824.
58. Chang AE, Shiling DJ, Stillman RC, et al. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. *Cancer*. 1981;47:1746-1751.
59. Levitt M, Faiman C, Hawks R, Wilson A. Randomized double-blind comparison of delta-9-tetrahydrocannabinol and marijuana as chemotherapy antiemetics. Proceedings of the Annual Meeting of the American Society of Clinical Oncology, Toronto, May 6-8, 1984.
60. Soderpalm A, Schuster A, de Wit H. Antiemetic efficacy of smoked marijuana. Subjective and behavioral effects on nausea induced by syrup of ipecac. *Pharmacol Biochem Behav*. 2001;69:343-350.
61. Abrams DI, Hilton JF, Leiser R et al. Short-term effects of cannabinoids in patients with HIV-1 infection. *Ann Intern Med*. 2003;139:258-266.
62. Haney M, Rabkin J, Gunderson E. Dronabinol and marijuana in HIV+ marijuana smokers: acute effects on caloric intake and mood. *Psychopharmacology*. 2005;181:170-178.
63. Haney M, Gunderson EW, Rabkin J, et al. Dronabinol and marijuana in HIV-positive marijuana smokers. *J Acquir Immune Defic Syndr*. 2007;45:545-554.

64. Wilsey B, Marcotte T, Tsodikov A, et al. A randomized, placebo-controlled crossover trial of cannabis cigarettes in neuropathic pain. *J Pain*. 2008;9:506-521.
65. Wallace M, Schulteis G, Atkinson JH, et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in health volunteers. *Anesthesiology*. 2007;107:785-796.
66. Abrams DI, Jay CA, Shade SB et al. Cannabis in painful HIV-associated sensory neuropathy. *Neurology*. 2007;68:515-521.
67. Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. *Neuropsychopharmacology*. 2009;34:672-680.
68. Nicholas PK, Kemppainen JK, Canaval GE, et al. Symptom management and self-care for peripheral neuropathy in HIV/AIDS. *AIDS Care*. 2007;19:179-189.
69. De Jong BC, Prentiss D, McFarland W, Machekano R, Israelski DM. Marijuana use and its association with adherence to antiretroviral therapy among HIV-infected person with moderate to severe nausea. *J Acquir Immune Defic Syndr*. 2005;38:43-46.
70. Prentiss D, Power R, Balmas G, Tzuang G, Israelski DM. Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. *J Acquir Immune Defic Syndr*. 2004;35:38-45.
71. Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A. Cannabis use in HIV for pain and other medical symptoms. *J Pain Symptom Manage*. 2005;29:358-367.
72. Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E. Cannabis use in patients with multiple sclerosis. *Multiple Sclerosis*. 2006;12:646-651.
73. Clark AJ, Ware MA, Yazer E, Murray TJ, Lynch ME. Patterns of cannabis use among patients with multiple sclerosis. *Neurology*. 2004;62:2098-2100.
74. Cory-Bloom J, Wolfson TJ, Gams AC, et al. Short-term effects of medicinal cannabis on spasticity in multiple sclerosis. Abstract.
75. Greenberg HS, Werness SA, Pugh JE, Andrus RO, Anderson DJ, Domino EF. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. *Clin Pharmacol Ther*. 1994;55:324-328.
76. Merrit JC, Crawford WJ, Alexander PC, Anduze AL, Gelbart SS. Effect of marijuana on intraocular and blood pressure in glaucoma. *Ophthalmology*. 1980;87:222-228
77. Wang T, Collet JP, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. *CMAJ*. 2008;178:1669-1678.
78. Substance Abuse and Mental Health Administration—Office of Applied Studies. Results from the 2007 National Survey on Drug Use and Health: national findings. <http://www.oas.samhsa.gov/nsduh/2k7nsduh/2k7Results.pdf>. Accessed August 10, 2009.

79. Chait LD, Pierri J. Effects of smoked marijuana on human performance: A critical review. In: Bartke A, Murphy L, eds. *Marijuana/Cannabinoids: Neurobiology and Neurophysiology*. CRC Press: Boca Raton, FL; 1992:387-424.
80. Hall W, Solowij N. Adverse effects of cannabis. *Lancet*. 1998;352:1611-1616.
81. Gorman DM, Huber CJ. Do medical cannabis laws encourage cannabis use? *Int J Drug Policy*. 2007;18:160-167.
82. Macleod J Oakes R, Copello A, et al. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal general population studies. *Lancet*. 2004;363:1579-1588.
83. Grant I, Gonzalez R, Carey CL, Natarajan L, Wolfson T. Non-acute (residual) neurocognitive effects of cannabis use: a meta analytic study. *J Int Neuropsychol Soc*. 2003;9:679-689.
84. Gonzalez R. Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. *Neuropsychol Rev*. 2007;17:347-361.
85. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. *Lancet*. 2007;370:319-328.
86. Roth MD, Arora A, Barsky SH, et al. Airway inflammation in young marijuana and tobacco smokers. *Am J Respir Crit Care Med*. 1998;157:928-937.
87. Taylor DR, Fergusson DM, Milne BJ, et al. A longitudinal study of the effects of tobacco and cannabis exposure on lung function in young adults. *Addiction*. 2002;97:1055-1061.
88. Aldington S, Williams M, Nowitz M, et al. Effects of cannabis on pulmonary structure, function and symptoms. *Thorax*. 2007;62:1058-1063.
89. Hashibe M, Morgenstern H, Cui Y, et al. Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. *Cancer Epidemiolo Biomarkers Prev*. 2006;15:1829-1834.
90. Liang C, McClean MD, Marsit C et al. A population-based case-control study of marijuana use and head and neck squamous cell carcinoma. *Cancer Prev Res*. 2009;2:759-768.
91. Tan WC, Lo C, Jong A et al. Marijuana and chronic obstructive lung disease: a population-based study. *CMAJ*. 2009;180:814-820.
92. Daling JR, Doody DR, Sun X et al. Association of marijuana use on the incidence of testicular germ cell tumors. *Cancer*. 2009;115:1215-1223.
93. Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL. Vaporization as a smokeless cannabis delivery system: a pilot study. *Clin Pharmacol Therapeut*. 2007;82:572-578.
94. Earlywine M, Barnwell SS. Decreased respiratory symptoms in cannabis users. *Harm Reduction J*. 2007;4:11.

95. Rieder SA, Chauhan A, Singh U, Nagarketti M, Nagarkatti P. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. *Immunobiology*. 2009 May 18. Epub ahead of print.
96. Klein TW, Cabral GA. Cannabinoid-induced immune suppression and modulation of antigen presenting cells. *J Neuroimmune Pharmacol*. 2006;1:50-64.
97. McHugh D, Tanner C, Mechoulam R, Pertwee R, Ross R. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: Evidence for a site distinct from CB1 and CB2. *Molecular Pharmacology*. 73:441-450.
98. Guzman M, Sanchez C, Galve-Roperh I. Cannabinoids and cell fate. *Pharmacol Ther*. 2002;95:175-184.
99. McKallip RJ, Nagarkatti M, Nagarkatti PS. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. *J Immunol*. 2005;174:3281-3289.
100. Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral. CB2 receptors in the brain: role in central immune function. *Brit J Pharmacol*. 2008;153:240-251.
101. Sylvestre DL, Clements BJ, Malibu Y. Cannabis use improves retention and virological outcomes in patients treatment for hepatitis C. *Eur J Gastroenterol Hepatol*. 2006;18:1057-1063.



APPENDIX A

AMA Policy On Medical Marijuana

H-95.952 Medical Marijuana

(1) Our AMA calls for further adequate and well-controlled studies of marijuana and related cannabinoids in patients who have serious conditions for which preclinical, anecdotal, or controlled evidence suggests possible efficacy and the application of such results to the understanding and treatment of disease. (2) Our AMA recommends that marijuana be retained in Schedule I of the Controlled Substances Act pending the outcome of such studies. (3) Our AMA urges the National Institutes of Health (NIH) to implement administrative procedures to facilitate grant applications and the conduct of well-designed clinical research into the medical utility of marijuana. This effort should include: a) disseminating specific information for researchers on the development of safeguards for marijuana clinical research protocols and the development of a model informed consent on marijuana for institutional review board evaluation; b) sufficient funding to support such clinical research and access for qualified investigators to adequate supplies of marijuana for clinical research purposes; c) confirming that marijuana of various and consistent strengths and/or placebo will be supplied by the National Institute on Drug Abuse to investigators registered with the Drug Enforcement Agency who are conducting bona fide clinical research studies that receive Food and Drug Administration approval, regardless of whether or not the NIH is the primary source of grant support. (4) Our AMA believes that the NIH should use its resources and influence to support the development of a smoke-free inhaled delivery system for marijuana or delta-9-tetrahydrocannabinol (THC) to reduce the health hazards associated with the combustion and inhalation of marijuana. (5) Our AMA believes that effective patient care requires the free and unfettered exchange of information on treatment alternatives and that discussion of these alternatives between physicians and patients should not subject either party to criminal sanctions. (CSA Rep. 10, I-97; Modified: CSA Rep. 6, A-01)

APPENDIX B

Institute of Medicine

**Marijuana and Medicine: Assessing the Science Base**

**RECOMMENDATION 1: Research should continue into the physiological effects of synthetic and plant-derived cannabinoids and the natural function of cannabinoids found in the body. Because different cannabinoids appear to have different effects, cannabinoids research should include, but not be restricted to, effects attributable to THC alone.**

Scientific data indicate the potential therapeutic value of cannabinoid drugs for pain relief, control of nausea and vomiting, and appetite stimulation. This value would be enhanced by a rapid onset of drug effect. (See Recommendation #2)

**RECOMMENDATION 2: Clinical trials of cannabinoid drugs for symptom management should be conducted with the goal of developing rapid-onset, reliable, and safe delivery systems.**

**RECOMMENDATION 3: Psychological effects of cannabinoids such as anxiety reduction and sedation, which can influence medical benefits, should be evaluated in clinical trials.**

The psychological effects of cannabinoids are probably important determinants of their potential therapeutic value. They can influence symptoms indirectly which could create false impressions of the drug effect or be beneficial as a form of adjunctive therapy.

**RECOMMENDATION 4: Studies to define the individual health risks of smoking marijuana should be conducted, particularly among populations in which marijuana use is prevalent.**

Numerous studies suggest that marijuana smoke is an important risk factor in the development of respiratory diseases, but the data that could conclusively establish or refute this suspected link have not been collected.

**RECOMMENDATION 5: Clinical trials of marijuana use for medical purposes should be conducted under the following limited circumstances: trials should involve only short-term marijuana use (less than six months), should be conducted in patients with conditions for which there is reasonable expectation of efficacy, should be approved by institutional review boards, and should collect data about efficacy.**

Because marijuana is a crude THC delivery system that also delivers harmful substances, smoked marijuana should generally not be recommended for medical use. Nonetheless, marijuana is widely used by certain patient groups, which raises both safety and efficacy issues. If there is any future for marijuana as a medicine, it lies in its isolated components, the cannabinoids and their synthetic derivatives. Isolated cannabinoids will provide more reliable effects than crude plant mixtures. Therefore, the purpose of clinical trials of smoked marijuana would not be to develop marijuana as a licensed drug but rather to serve as a first step toward the development of nonsmoked rapid-onset cannabinoid delivery systems.

**RECOMMENDATION 6: Short-term use of smoked marijuana (less than six months) for patients with debilitating symptoms (such as intractable pain or vomiting) must meet the following conditions:**

- failure of all approved medications to provide relief has been documented,
- the symptoms can reasonably be expected to be relieved by rapid-onset cannabinoid drugs,
- such treatment is administered under medical supervision in a manner that allows for assessment of treatment effectiveness, and
- involves an oversight strategy comparable to an institutional review board process that could provide guidance within 24 hours of a submission by a physician to provide marijuana to a patient for a specified use.

Appendix C

American College of Physicians Position Statement

**Position 1:** ACP supports programs and funding for rigorous scientific evaluation of the potential therapeutic benefits of medical marijuana and the publication of such findings.

- Position 1a: ACP supports increased research for conditions where the efficacy of marijuana has been established to determine optimal dosage and route of delivery.
- Position 1b: Medical marijuana research should not only focus on determining drug efficacy and safety but also on determining efficacy in comparison with other available treatments.

**Position 2:** ACP encourages the use of nonsmoked forms of THC that have proven therapeutic value.

**Position 3:** ACP supports the current process for obtaining federal research-grade cannabis.

**Position 4:** ACP urges an evidence-based review of marijuana's status as a Schedule I controlled substance to determine whether it should be reclassified to a different schedule. This review should consider the scientific findings regarding marijuana's safety and efficacy in some clinical conditions as well as evidence on the health risks associated with marijuana consumption, particularly in its crude smoked form.

**Position 5:** ACP strongly supports exemption from federal criminal prosecution; civil liability; or professional sanctioning, such as loss of licensure or credentialing, for physicians who prescribe or dispense medical marijuana in accordance with state law. Similarly, ACP strongly urges protection from criminal or civil penalties for patients who use medical marijuana as permitted under state laws.

Table 1. Randomized, Placebo-Controlled Trials of Smoked Cannabis					
Study	n	Design	Product and dosage	Efficacy	Adverse Effects
<i>Antiemetic effects in patients receiving cancer chemotherapy</i>					
Chang et al <sup>57</sup>	15 patients with osteogenic sarcoma undergoing high dose methotrexate chemotherapy (median age 24 years)	R, DB, CR, PC	Oral THC 10 mg/m <sup>2</sup> 5 times daily or smoked cannabis (1.93% THC) cigarette substituted if vomiting occurred	Oral THC alone or the combination of oral and smoked cannabis had an antiemetic effect > placebo. THC reduced the number of retching and vomiting episodes, the degree and duration of nausea, and the volume of emesis. Clinical responses appeared to correlate with plasma THC values. Smoked THC yielded plasma concentrations more than 5 ng/mL on 70% of occasions compared with 44% of the time with oral THC.	Sedation in 80% of patients, most of whom had prior experience with smoked cannabis
Chang et al <sup>58</sup>	8 patients with various tumors undergoing adjuvant therapy with doxorubicin and cyclophosphamide (median age 41 years)	R, DB, CR, PC	Oral THC 10 mg/m <sup>2</sup> 5 times daily or smoked cannabis (1.93% THC) cigarette substituted if vomiting occurred	No antiemetic effect. Seven of eight patients inexperienced in the use of cannabis.	Mood alteration and episodes of tachycardia
Levitt et al <sup>59</sup>	20 patients with various tumors	R, DB, CR, PC	One cannabis cigarette + placebo oral THC x 4; oral THC 15 mg + placebo cannabis cigarette x 4	Treatments were effective in only in 25% of patients; 35% preferred oral THC; 20% preferred smoked cannabis; 45% had nor preference.	Seven individuals exhibited distortions of time perception or hallucinations; four that had received THC; two with cannabis, and one with both
<i>Appetite stimulation</i>					
Abrams et al <sup>61</sup>	67 adults with HIV infection	R, DB for oral THC or P, PL	One to three cannabis cigarettes/day (3.95% THC) or oral THC 2.5 mg tid for 21 days	Smoked cannabis and oral THC equivalent on weight gain and superior to placebo; viral load and pharmacokinetics of protease inhibitors unaffected	Generally well tolerated; one cannabis recipient discontinued due to emergence of neuropsychiatric symptoms; two oral THC recipients dropped out due to side effects (paranoia, headache)

Haney et al <sup>62</sup>	30 HIV+ experienced cannabis smokers, half with less than 90% ideal body mass	R, DB, PC	Dronabinol zero to 30 mg or cannabis cigarettes zero to 3.9% THC, administered in eight 7 hour sessions over three to four weeks	Cannabis and dronabinol significantly increased caloric intake in the low body mass group	Few adverse effects reports, except intolerance of high (30 mg) dronabinol dose
Haney et al <sup>63</sup>	10 HIV+ experienced cannabis smokers	R, DB, PC	Dronabinol 5 or 10 mg, or cannabis cigarettes 2% or 3.9% THC each four times daily for four days	Cannabis and dronabinol increased caloric intake in a dose dependent fashion, and body weight at the highest doses	Relative absence of cognitive impairment. Improved mood and objective and subjective sleep measures.
<i>Pain Management/Analgesia</i>					
Abrams et al <sup>66</sup>	55 patients with HIV-associated neuropathic pain	R, DB, PC, PL	Up to three cannabis (3.95% THC) cigarettes daily for 5 days	Smoked cannabis relieved chronic neuropathic pain (34% reduction), and more than 50% of patients experienced at least a 30% reduction in pain intensity. Smoked cannabis also reduced experimentally induced hyperalgesia	All patients had prior cannabis smoking experience. Anxiety, sedation, disorientation, confusion, and dizziness occurred more often in cannabis recipients, but were rated as between “none” and mild.
Ellis et al <sup>67</sup>	34 adult patients with HIV-associated neuropathic pain	R, DB, CR, PC	Cannabis cigarettes of varying THC concentration (1-8%) administered 4 times daily for 5 days	46% more patients achieved at least a 30% reduction in pain relief with cannabis vs placebo	All patients were taking additional analgesics. Concentration difficulties, fatigue, sedation, dry mouth, tachycardia more frequent but not dose limiting. Two dropouts for “psychosis” and “cough”
Wilsey et al <sup>64</sup>	38 adult patients experienced cannabis smokers with central and peripheral neuropathic pain	R, DB, CR, PC	Cannabis cigarettes zero, 3.5% or 7% THC administered in graded puffs over 2 hours	Smoked cannabis reduced pain intensity at 4 hours compared with placebo; no difference was noted between the 2 doses. No effects observed on evoked pain responses. Most patients had complex regional pain syndrome.	Cannabis recipients were more likely to report subjective and psychoactive drug effects including impairment and sedation. General cognitive decline on psychological testing.

<i>Multiple sclerosis</i>					
Greenberg et al <sup>75</sup>	10 adult patients with multiple sclerosis and spasticity	R, DB, PC	One cannabis cigarette (1.54% THC) smoked over 10 minutes	Subjective feeling of clinical improvement in some patients	Impairment of posture and balance as measured by dynamic posturography
Cory-Bloom et al <sup>74</sup>	30 adult patients with multiple sclerosis and spasticity	R, DB, CR, PC	One cannabis cigarette (3.95%) daily for 3 days	Reduced pain (~50%) and spasticity (~30%) scores.	Cognitive impairment; dizziness; fatigue, "too high." 80% had prior cannabis use
<i>Glaucoma</i>					
Merritt et al <sup>76</sup>	18 adults with glaucoma (ages 28-71)	R, DB, CR, PC	One cannabis cigarette containing 2% THC	Significant reduction in intraocular pressure	Alteration in sensory perception (100%); tachycardia and palpitations (44%), postural hypotension (28%)

R = randomized; DB = double-blind; CR = crossover trials, PL = parallel group study; PC = placebo-controlled